Allergy Therapeutics
Key data on track, return to growth expected next yearAllergy Therapeutics
Solid commercial performance with major R&D upsideAllergy Therapeutics
FDA green lights VLP Peanut vaccine Phase I trialAllergy Therapeutics
Commercialising and developing a differentiated portfolioAllergy Therapeutics
Positive top line G309 results for Grass MATA MPLAllergy Therapeutics
FY21 results show continued strong growthAllergy Therapeutics
VLP Peanut heading towards US Phase I studiesAllergy Therapeutics
Biomarker data confirm VLP Peanut hypoallergenicityAllergy Therapeutics
Strong FY21 trading, but pipeline set to drive futureAllergy Therapeutics
FY21 pre-close update ahead of market expectations